Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1.(currently amended) A compound having the formula



(I)

~~or~~



(II)

in which:

R_0 is selected from the group consisting of C_1- C_3 alkyl, cyclopropyl, halo, OR_5 and $S(O)_mR_5$ in which *m* is 0, 1 or 2;

R_1 and R_2 are independently selected from the group consisting of C_2-C_8 alkenyl, phenylcyclopropyl, phenylpropenyl, R_6-X_2-$C(R_8)(R_8)$-R_7-; and R_6-X_2-$N(R_8)$-R_7-;

or R_2 is $(CH_2)_{m'}C_6H_5$ wherein m' is 0 or an integer from 1 to 3, or R_2 is C_3-C_6 cycloalkyl;

R_3 and R_4 are independently hydrogen, methyl or ethyl;

R_5 is methyl or ethyl;

R_6 is selected from the group consisting of hydrogen, C_1-C_{10} alkyl, aryl, W, Y, NH_2, $NHCONR_3R_4$, $NHCOOR_3$ and $NHSO_2R_9$;

R_7 is selected from the group consisting of a direct bond, an alkyl group having from 1 to 10 carbon atoms, aryl, $-(NH)_p(CH_2CH_2O)_q(NH)_p-$ in which *p* is 0 or 1 and *q* is an integer from 1 to 4, and W;

R_8 is selected from the group consisting of H, Y, OH, $-NHCONR_3R_4$; $-NHCOOR_3$;

$-NHSO_2R_9$, $-(CH_2)_rCO_2R_3$, and $(CH_2)_rCO_2NR_3R_4$ in which *r* is an integer from 1 to 3;

R_9 is aryl or C_1-C_6 alkyl;

X_1 is -CH-, -C-hal, $-C(CH_3)$ or $-C(C_2H_5)$, in which *hal* stands for a halogen atom (preferably chloro, fluoro or bromo);

X_2 is selected from the group consisting of a direct bond, -NH-, $-N(CH_3)-$, $-NCONR_3R_4-$, $-NCOOR_3-$, and NSO_2R_9;

W is a saturated carbocyclic or heterocyclic group;

Y is selected from the group consisting of COOH, $COOR_3$, $CONR_3R_4$, $CONHSO_2R_5$, hydroxymethyl, $-CH_2COOH$, $CH_2CONR_3R_4$; and 5-tetrazolyl; and

Z is $-CH_2-$, $-CH(CH_3)-$, $C(CH_3)_2-$ or -CO-;

and hydrates and salts thereof, and labeled derivatives thereof.

2.(canceled)

3.(withdrawn) A compound of Formula (II) according to claim 1.

4.(original) A compound according to claim 1 in which Y is COOH or $COOR_3$.

5 .(currently amended) A compound according to ~~claims~~ claim 1 in which R_0 is a C_1- C_3 alkyl group.

6.(original) A compound according to claim 5 in which R_0 is methyl.

7.(currently amended) A compound according to claim ~~2~~ 1 in which R_1 is optionally substituted phenethyl.

8.(currently amended) A compound according to claim ~~2~~ 1 in which R_1 is 2-hydroxyethyl.

9.(currently amended) A compound according to claim ~~2~~ 1 in which R_2 is n-butyl, phenyl or 1-hydroxy- n-butyrylamido.

10.(currently amended) A compound according to claim ~~2~~ 1 in which R_2 is R_6-X_2-$C(R_8)(R_8)$-R_7- or R_6-X_2-$N(R_8)$-R_7-, and the group R_6-X_2-$C(R_8)(R_8)$-R_7- or R_6-X_2-$N(R_8)$-R_7- is selected from C_3-C_8 alkyl; C_3-C_6 cycloalkyl; C_3-C_8 alkenyl; ~~$-(CH_2)_m C_6H_5$~~ $(CH_2)_{m'}C_6H_5$ where ~~*m*~~ *m'* is 0 or an integer from 1-3; $-CH_2OC_6H_5$, $CH_2COC_6H_5$, phenyl(C_2-C_4 alkenyl), or analogous moieties having substituted phenyl groups; optionally substituted phenylcyclopropyl; $-(CH_2)_sOH$, $-(CH_2)_sCONH_2$ and $-(CH_2)_sCOOH$ where *s* is an integer from 1 to 3; phenyl; thienyl; and optionally substituted C_3-C_6 cycloalkyl-(C_1-C_3 alkyl).

11.(withdrawn; currently amended) A compound according to claim ~~2~~ 1 in which R_0 is methyl, R_1 is phenethyl, R_2 is n-butyl, X_1 is -CH, Y is COOH and *n* is 0.

12.(withdrawn; currently amended) A compound according to claim ~~2~~ 1 in which R_0 is methyl, R_1 is 2-hydroxyethyl, R_2 is n-butyl, X_1 is -CH, Y is COOH and *n* is 0.

13.(original) A compound according to claim 3 in which R_2 is phenethyl or 2-hydroxyethyl.

14.(original) A compound according to claim 3 in which R_1 is C_3-C_8 alkyl.

15.(original) A compound according to claim 3 in which R_0 is methyl, R_1 is n-pentyl, R_2 is phenethyl, X_1 is -CH and Y is COOH.

16.(original) A probe comprising a compound according to claim 1 and a detectable label.

17.(withdrawn) A method for inhibiting the functioning of a PDZ domain of a protein comprising contacting the protein with an inhibitory effective amount of a compound according to claim 1.

18.(withdrawn) A method for inhibiting the functioning of a PDZ domain of a protein comprising contacting the protein with an inhibitory effective amount of a compound according to claim 2.

19.(withdrawn) A method for inhibiting the functioning of a PDZ domain of a protein comprising contacting the protein with an inhibitory effective amount of a compound according to claim 3.

20.(withdrawn) A method for inhibiting the functioning of a PDZ domain of a protein comprising contacting the protein with an inhibitory effective amount of a compound according to claim 7.

21.(withdrawn) A method for inhibiting the functioning of a PDZ domain of a protein comprising contacting the protein with an inhibitory effective amount of a compound according to claim 8.

22.(withdrawn) A method for inhibiting the functioning of a PDZ domain of a protein comprising contacting the protein with an inhibitory effective amount of a compound according to claim 9.

23.(withdrawn) A method for inhibiting the functioning of a PDZ domain of a protein comprising contacting the protein with an inhibitory effective amount of a compound according to claim 10.

24.(withdrawn) A method for inhibiting the functioning of a PDZ domain of a protein comprising contacting the protein with an inhibitory effective amount of a compound according to claim 11.

25.(withdrawn) A method for inhibiting the functioning of a PDZ domain of a protein comprising contacting the protein with an inhibitory effective amount of a compound according to claim 15.

26.(withdrawn) A method according to claim 17 in which the protein is a MAGI protein.

27.(currently amended) A combinatorial library of two or more compounds having the formula



~~(I)~~

~~or~~



~~(II)~~

in which:

R_0 is selected from the group consisting of C_1- C_3 alkyl, cyclopropyl, halo, OR_5 and $S(O)_mR_5$ in which *m* is 0, 1 or 2;

R_1 and R_2 are independently selected from the group consisting of C_2-C_8 alkenyl, phenylcyclopropyl, phenylpropenyl,), R_6-X_2-$C(R_8)(R_8)$-R_7-; and R_6-X_2-$N(R_8)$-R_7-;

or R_2 is phenyl;

R_3 and R_4 are independently hydrogen, methyl or ethyl;

R_5 is methyl or ethyl;

R_6 is selected from the group consisting of hydrogen, C_1-C_{10} alkyl, aryl, W, Y, NH_2, $NHCONR_3R_4$, $NHCOOR_3$ and $NHSO_2R_9$;

R_7 is selected from the group consisting of a direct bond, an alkyl group having from 1 to 10 carbon atoms, aryl, $-(NH)_p(CH_2CH_2O)_q(NH)_p-$ in which *p* is 0 or 1 and *q* is an integer from 1 to 4, and W;

R_8 is selected from the group consisting of H, Y, OH, $-NHCONR_3R_4$; $-NHCOOR_3$;

$-NHSO_2R_9$, $-(CH_2)_rCO_2R_3$, and $(CH_2)_rCO_2NR_3R_4$ in which *r* is an integer from 1 to 3;

R_9 is aryl or C_1-C_6 alkyl;

X_1 is -CH-, -C-hal, $-C(CH_3)$ or $-C(C_2H_5)$, in which *hal* stands for a halogen atom (preferably chloro, fluoro or bromo);

X_2 is selected from the group consisting of a direct bond, -NH-, $-N(CH_3)$-, $-NCONR_3R_4$-, $-NCOOR_3$-, and NSO_2R_9;

W is a saturated carbocyclic or heterocyclic group;

Y is selected from the group consisting of COOH, $COOR_3$, $CONR_3R_4$, $CONHSO_2R_5$, hydroxymethyl, $-CH_2COOH$, $CH_2CONR_3R_4$; and 5-tetrazolyl; and

Z is $-CH_2-$, $-CH(CH_3)-$, $C(CH_3)_2-$ or -CO-;

and hydrates and salts thereof, and labeled derivatives thereof.

28.(canceled)

29.(withdrawn) A combinatorial library according to claim 27 in which the compounds are of Formula (II).

30.(withdrawn) A method for screening one or more proteins for PDZ domain activity comprising contacting the one or more proteins with a compound according to claim 1.

31.(withdrawn) An array for screening for PDZ domain activity or inhibition of the same, or for studying protein-protein interactions comprising two or more compounds according to claim 1.

32.(withdrawn) A method for treating a cancer in cancerous cells or in a patient comprising contacting the cancerous cells with, or administering to the patient, a therapeutically effective amount of a compound according to claim 1.

33.(withdrawn) A method for treating a cancer in a patient comprising administering to the patient a therapeutically effective amount of a compound according to claim 2.

34.(withdrawn) A method for treating a cancer in a patient comprising administering to the patient a therapeutically effective amount of a compound according to claim 3.

35.(withdrawn) A method for treating a cancer in a patient comprising administering to the patient a therapeutically effective amount of a compound according to claim 11.

36.(withdrawn) A method for treating a cancer in a patient comprising administering to the patient a therapeutically effective amount of a compound according to claim 15.